Terms: = Endocrine gland cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Prognosis
10 results:
1. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
2. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Fu D; Yan J; Zhang Z; Liu Y; Ma X; Ding J; Yang S; Zhao R; Chang A; Gao C; Liu J; Zhao T; Wang X; Huang C; Gao S; Ma Y; Tang B; Feng Y; Wang H; Hao J
Cancer Biol Med; 2023 Jun; 20(8):599-626. PubMed ID: 37381714
[TBL] [Abstract] [Full Text] [Related]
3. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by jak1, STAT1 and IRF1 signaling.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
[TBL] [Abstract] [Full Text] [Related]
4. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study.
Zou S; Wang X; Chen H; Lin J; Wen C; Zhan Q; Chen H; Lu X; Deng X; Shen B
BMC Cancer; 2022 Jun; 22(1):649. PubMed ID: 35698045
[TBL] [Abstract] [Full Text] [Related]
5. microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting jak1.
Zhong R; Li S; Fang K; Yang L; Wang L
Cell Cycle; 2019 May; 18(9):990-1000. PubMed ID: 30990343
[TBL] [Abstract] [Full Text] [Related]
6. Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
Al-Hader A; Al-Rohil RN; Han H; Von Hoff D
World J Gastroenterol; 2017 Dec; 23(45):7945-7951. PubMed ID: 29259370
[TBL] [Abstract] [Full Text] [Related]
7. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic cancer for Whom Therapy With Gemcitabine Has Failed.
Hurwitz HI; Uppal N; Wagner SA; Bendell JC; Beck JT; Wade SM; Nemunaitis JJ; Stella PJ; Pipas JM; Wainberg ZA; Manges R; Garrett WM; Hunter DS; Clark J; Leopold L; Sandor V; Levy RS
J Clin Oncol; 2015 Dec; 33(34):4039-47. PubMed ID: 26351344
[TBL] [Abstract] [Full Text] [Related]
8. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract] [Full Text] [Related]
9. Targeting jak1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Wen W; Liang W; Wu J; Kowolik CM; Buettner R; Scuto A; Hsieh MY; Hong H; Brown CE; Forman SJ; Horne D; Morgan R; Wakabayashi M; Dellinger TH; Han ES; Yim JH; Jove R
Mol Cancer Ther; 2014 Dec; 13(12):3037-48. PubMed ID: 25319391
[TBL] [Abstract] [Full Text] [Related]
10. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
Jiao Y; Yonescu R; Offerhaus GJ; Klimstra DS; Maitra A; Eshleman JR; Herman JG; Poh W; Pelosof L; Wolfgang CL; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N; Wood LD
J Pathol; 2014 Mar; 232(4):428-35. PubMed ID: 24293293
[TBL] [Abstract] [Full Text] [Related]